热门资讯> 正文

Neumora Therapeutics GAAP每股收益为-0.33美元

2025-08-07 05:53

Neumora Therapeutics press release (NASDAQ:NMRA): Q2 GAAP EPS of -$0.33.
Cash Position: As of June 30, 2025, Neumora had cash, cash equivalents and marketable securities of $217.6 million.
Financial Guidance: The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2025, will enable it to fund its operating plan into 2027.

More on Neumora Therapeutics

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Seeking Alpha’s Quant Rating on Neumora Therapeutics
Historical earnings data for Neumora Therapeutics
Financial information for Neumora Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。